Kansikuva

Barriers to access to hepatitis C treatment with direct-acting antivirals in people who inject drugs in the community setting

Abstract Barriers to access to hepatitis C treatment with direct-acting antivirals in people who inject drugs in the community setting. Qualitative study with prison population. Hepatitis C (HCV) treatments with direct-acting antiviral therapy (DAA) are an easy and effective option among people who...

Tallennettuna:

Bibliografiset tiedot
Päätekijät:	Elena Yela (Tekijä), Neus Solé (Tekijä), Lidia Puig (Tekijä), Darío López Gallegos (Tekijä), Rafael Clua-García (Tekijä)
Aineistotyyppi:	Kirja
Julkaistu:	BMC, 2024-04-01T00:00:00Z.
Aiheet:	article
Linkit:	Connect to this object online.
Tagit:	Lisää tagi Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia

Accessing hepatitis C direct acting antivirals among people living with hepatitis C: a qualitative study
Tekijä: Tony Antoniou, et al.
Julkaistu: (2023)

Rate of hepatitis C reinfection after successful direct-acting antivirals treatment among people who inject drugs in Spain: the LIVERate study
Tekijä: Fernando Chacón, et al.
Julkaistu: (2024)

Correction: Accessing hepatitis C direct acting antivirals among people living with hepatitis C: a qualitative study
Tekijä: Tony Antoniou, et al.
Julkaistu: (2023)

Bioequivalent pharmacokinetics for generic and originator hepatitis C direct-acting antivirals
Tekijä: Andrew Hill, et al.
Julkaistu: (2018)

P28 Queensland injectors health network (QuIHN) treatment management program (TMP): hepatitis C virus (HCV) direct acting antivirals (DAA) full access for people who inject drugs
Tekijä: R. Kavanagh, et al.
Julkaistu: (2017)

IP-10 Interferes With the Antiviral Response of Direct-Acting Antiviral Agents for Hepatitis C Virus Infection
Tekijä: Yadong Wang, et al.
Julkaistu: (2022)

P55 Client acceptability and feasibility of expanded access to direct acting antiviral therapy for hepatitis at the Kirketon Road Centre
Tekijä: K.J. Chronister, et al.
Julkaistu: (2017)

P54 Treatment adherence among people who inject drugs taking directly observed direct acting antiviral therapy at Kirketon Road Centre
Tekijä: K.J. Chronister, et al.
Julkaistu: (2017)

Patient and healthcare provider experiences of hepatitis C treatment with direct-acting antivirals in Rwanda: a qualitative exploration of barriers and facilitators
Tekijä: Janvier Serumondo, et al.
Julkaistu: (2020)

Combining treatment for chronic hepatitis C with opioid agonist therapy is an effective microelimination strategy for people who inject drugs with high risk of non-adherence to direct-acting antiviral therapy
Tekijä: M. Schwarz, et al.
Julkaistu: (2023)

P20 Monitoring the uptake of hepatitis C: direct acting antiviral treatment in Australia
Tekijä: B. Hajarizadeh, et al.
Julkaistu: (2017)

Adoption of direct-acting antiviral medications for hepatitis C: a retrospective observational study
Tekijä: Leah L. Zullig, et al.
Julkaistu: (2019)

The effect of cognitive emotion regulation on direct-acting antivirals adherence in patients with hepatitis C
Tekijä: Adina Turcu-Stiolica, et al.
Julkaistu: (2024)

Strategies for treating and managing chronic hepatitis C in children in the direct-acting antiviral era
Tekijä: Suk-Jin Hong, et al.
Julkaistu: (2020)

Autoimmune hepatitis associated Hepatitis C virus infection treated with fi rst generation direct-acting antivirals
Tekijä: Juan Diego Castro Limo, et al.
Julkaistu: (2019)

Virus infection and direct-acting antivirals in pregnancy
Tekijä: Xuan Huang, et al.
Julkaistu: (2022)

Continuum of hepatitis C care cascade in prison and following release in the direct-acting antivirals era
Tekijä: Sanam Hariri, et al.
Julkaistu: (2020)

Hepatitis C virus pharmacogenomics in Latin American populations: implications in the era of direct-acting antivirals
Tekijä: Trinks J, et al.
Julkaistu: (2017)

Retrospective Evaluation on Patient Screening and Counseling Service on Direct-acting Antivirals Against Hepatitis C
Tekijä: Bob Ka Him Wong, et al.
Julkaistu: (2020)

Effect of direct-acting antivirals on elastographic measures in patients with chronic hepatitis C virus infection
Tekijä: Mohamed M Sakr, et al.
Julkaistu: (2019)

Direct-acting antivirals for chronic Hepatitis C are effective and safe: an observational study in Londrina/PR
Tekijä: Hodnei Takashi Machado, et al.
Julkaistu: (2022)

Barriers to Completing Therapy for Hepatitis C with Direct-Acting Antivirals: A Real-Life Experience from a Single Treatment Center in Egypt
Tekijä: Marwa M. Ahmed, et al.
Julkaistu: (2021)

Facilitators of HCV treatment adherence among people who inject drugs: a systematic qualitative review and implications for scale up of direct acting antivirals
Tekijä: Zachary C. Rich, et al.
Julkaistu: (2016)

Perceived physical health outcomes of direct-acting antiviral treatment for hepatitis C: a qualitative study
Tekijä: Stelliana Goutzamanis, et al.
Julkaistu: (2021)

Hepatitis C: sociodemographic and clinical profile of patients treated with direct-acting antivirals in a pharmaceutical office
Tekijä: Karem Aline Pegoraro, et al.
Julkaistu: (2023)

Predicting Treatment Failure for Initiators of Hepatitis C Virus Treatment in the era of Direct-Acting Antiviral Therapy
Tekijä: Nadia A. Nabulsi, et al.
Julkaistu: (2020)

Patients' preferences for treatment with the new direct acting antiviral therapies for chronic hepatitis C virus infection
Tekijä: MA Simón, et al.
Julkaistu: (2021)

Is direct-acting antiviral treatment beneficial or harmful for patients with hepatitis C virus-related hepatocellular carcinoma?
Tekijä: Hye Won Lee
Julkaistu: (2022)

Enhanced liver fibrosis score as a noninvasive biomarker in hepatitis C virus patients after direct-acting antiviral agents
Tekijä: Valentina Cossiga, et al.
Julkaistu: (2022)

Evaluation of pharmaceutical intervention in direct-acting antiviral agents for hepatitis C virus infected patients in an ambulatory setting: a retrospective analysis
Tekijä: Haruna Yamamoto, et al.
Julkaistu: (2018)

Uptake of hepatitis C direct-acting antiviral treatment in China: a retrospective study from 2017 to 2021
Tekijä: Xinyu Du, et al.
Julkaistu: (2023)

Reported adverse events related to use of hepatitis C virus direct-acting antivirals with opioids: 2017-2021
Tekijä: Anthony Martinez, et al.
Julkaistu: (2023)

Interventions to Improve Uptake of Direct-Acting Antivirals for Hepatitis C Virus in Priority Populations: A Systematic Review
Tekijä: David Ortiz-Paredes, et al.
Julkaistu: (2022)

Price of a hepatitis C cure: Cost of production and current prices for direct-acting antivirals in 50 countries
Tekijä: Melissa J. Barber, et al.
Julkaistu: (2020)

Evaluation of the effect of direct-acting antiviral agents on melatonin level and lipid peroxidation in chronic hepatitis C patients
Tekijä: Nageh Ahmed El-Mahdy, et al.
Julkaistu: (2023)

High sustained virological response rates using imported generic direct acting antiviral treatment for hepatitis C
Tekijä: Andrew Hill, et al.
Julkaistu: (2017)

Impact of drug use policy on the appropriate use of direct acting antiviral agents for Hepatitis C in Saudi Arabia
Tekijä: Ahmed Saqer Alotaibi, et al.
Julkaistu: (2021)

Role of different direct-acting antiviral drugs on hepatitis C virus-associated mixed cryoglobulinemia in Egyptian patients
Tekijä: Tarek A Elshazly, et al.
Julkaistu: (2019)

The need for a European hepatitis C programme monitoring resistance to direct-acting antiviral agents in real life to eliminate hepatitis C
Tekijä: Stephanie Popping, et al.
Julkaistu: (2018)

Direct Acting Antiviral Drugs: Pharmacokinetics and Drug-Drug Interactions
Tekijä: Marina Barakat, et al.
Julkaistu: (2022)